Keryx Biopharmaceuticals, Inc. (KERX) Posts Q3 Loss of $0.15
Tweet
Share
E-mailGet Alerts KERX Hot Sheet
Join SI Premium – FREE
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q3 EPS of ($0.15), $0.03 worse than the analyst estimate of ($0.12).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
